Fund shareholders of AVALO THERAPEUTICS INC
ISIN US05338F3064 · United States · LEI 549300GPK6FPJ3X8SZ39
- Fund shareholders
- 119
- Of which ETFs
- 17 102 other funds
- Value held
- 251.9M $
- Share of capital
- 25.7 % of 53.6M shares on Aug 3, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| iShares Health Innovation Active ETF BlackRock ETF Trust | 781 | 14.3K $ | 0.13 % | 0.00 % | as of Jul 31, 2026 ↗ |
| JNL/DFA U.S. Small Cap Fund JNL Series Trust | 746 | 13.8K $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| GMO U.S. Small Cap Value Fund GMO TRUST | 593 | 9.5K $ | 0.02 % | 0.00 % | as of May 31, 2026 ↗ |
| Nuveen Life Stock Index Fund TIAA-CREF Life Funds | 565 | 10.4K $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| ULTRA SMALL CAP PROFUND ProFunds | 538 | 9.8K $ | 0.02 % | 0.00 % | as of Jul 31, 2026 ↗ |
| T. Rowe Price Innovation Leaders ETF T. Rowe Price Exchange-Traded Funds, Inc. | 430 | 7.9K $ | 0.04 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Total Stock Market Index Trust John Hancock Variable Insurance Trust | 374 | 6.9K $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| State Street Balanced Index Fund STATE STREET INSTITUTIONAL INVESTMENT TRUST | 293 | 5.4K $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Russell 2000 2x Strategy Fund Rydex Dynamic Funds | 225 | 4.2K $ | 0.01 % | 0.00 % | as of Jun 30, 2026 ↗ |
| PROFUND VP ULTRA SMALL CAP ProFunds | 172 | 3.2K $ | 0.02 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Knights of Columbus U.S. ALL CAP INDEX FUND ADVISORS' INNER CIRCLE III | 149 | 2.7K $ | 0.00 % | 0.00 % | as of Jul 31, 2026 ↗ |
| Dimensional US Vector Equity ETF Dimensional ETF Trust | 140 | 2.6K $ | 0.00 % | 0.00 % | as of Jul 31, 2026 ↗ |
| PROFUND VP SMALL CAP ProFunds | 112 | 2.1K $ | 0.02 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Russell 2000 Fund Rydex Series Funds | 104 | 1.9K $ | 0.01 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Russell 2000 1.5x Strategy Fund Rydex Series Funds | 62 | 1.1K $ | 0.02 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Columbia Research Enhanced Small Cap ETF Columbia ETF Trust I | 56 | 1K $ | 0.03 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Fidelity Enhanced Small Cap Growth ETF Fidelity Covington Trust | 42 | 776.2 $ | 0.01 % | 0.00 % | as of Jun 30, 2026 ↗ |
| SMALL-CAP PROFUND ProFunds | 35 | 638.8 $ | 0.01 % | 0.00 % | as of Jul 31, 2026 ↗ |
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 12 | 221.8 $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Virtus Biotech Clinical Trials Etf ETFis Series Trust I | 0.83 % | as of Jul 31, 2026 ↗ |
| Fidelity Advisor Biotechnology Fund Fidelity Advisor Series VII | 0.53 % | as of Jul 31, 2026 ↗ |
| Small Cap Core Portfolio Bernstein Fund Inc | 0.41 % | as of Jun 30, 2026 ↗ |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 0.35 % | as of Jun 30, 2026 ↗ |
| T. Rowe Price Health Care ETF T. Rowe Price Exchange-Traded Funds, Inc. | 0.34 % | as of Jun 30, 2026 ↗ |
| PROFUND VP BIOTECHNOLOGY ProFunds | 0.34 % | as of Jun 30, 2026 ↗ |
| Fidelity Small Cap Discovery Fund Fidelity Concord Street Trust | 0.31 % | as of Jul 31, 2026 ↗ |
| Fidelity Series Small Cap Discovery Fund Fidelity Concord Street Trust | 0.31 % | as of Jul 31, 2026 ↗ |
| Fidelity Stock Selector Small Cap Fund Fidelity Capital Trust | 0.30 % | as of Jul 31, 2026 ↗ |
| BIOTECHNOLOGY ULTRASECTOR PROFUND ProFunds | 0.30 % | as of Jul 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q3 | 119 | +78 | 13,785,493 | +194.4 % |
| 2026Q2 | 41 | +18 | 4,682,028 | +336.7 % |
| 2026Q1 | 23 | +6 | 1,072,062 | +10.4 % |
| 2025Q4 | 17 | +10 | 970,781 | +247.3 % |
| 2025Q3 | 7 | +2 | 279,520 | +8.3 % |
| 2025Q2 | 5 | 0 | 258,129 | +48.0 % |
| 2025Q1 | 5 | 0 | 174,411 | +786.6 % |
| 2024Q4 | 5 | -2 | 19,672 | -2.4 % |
| 2024Q3 | 7 | 0 | 20,160 | +139.2 % |
| 2024Q2 | 7 | +3 | 8,429 | -46.6 % |
| 2024Q1 | 4 | 15,776 |
Institutional managers
93 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| FMR LLC | 2,879,481 | 43M $ | as of Mar 31, 2026 |
| T. Rowe Price Investment Management, Inc. | 2,162,684 | 32.3K $ | as of Mar 31, 2026 |
| Caligan Partners LP | 1,635,023 | 24.4M $ | as of Mar 31, 2026 |
| BVF INC/IL | 1,632,845 | 24.4M $ | as of Mar 31, 2026 |
| Avoro Capital Advisors LLC | 1,410,000 | 21.1M $ | as of Mar 31, 2026 |
| Affinity Asset Advisors, LLC | 1,340,840 | 20M $ | as of Mar 31, 2026 |
| Nantahala Capital Management, LLC | 1,235,000 | 18.4M $ | as of Mar 31, 2026 |
| UBS Group AG | 1,141,980 | 17M $ | as of Mar 31, 2026 |
| Point72 Asset Management, L.P. | 916,142 | 13.7M $ | as of Mar 31, 2026 |
| FARALLON CAPITAL MANAGEMENT LLC | 916,000 | 13.7M $ | as of Mar 31, 2026 |
| RTW INVESTMENTS, LP | 856,962 | 12.8M $ | as of Mar 31, 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 854,000 | 12.8M $ | as of Mar 31, 2026 |
| MILLENNIUM MANAGEMENT LLC | 835,484 | 12.5M $ | as of Mar 31, 2026 |
| TCG Crossover Management, LLC | 738,383 | 11M $ | as of Mar 31, 2026 |
| Balyasny Asset Management L.P. | 731,586 | 10.9M $ | as of Mar 31, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 662,968 | 9.9M $ | as of Mar 31, 2026 |
| BANK OF AMERICA CORP /DE/ | 643,000 | 9.6M $ | as of Mar 31, 2026 |
| Commodore Capital LP | 483,000 | 7.2M $ | as of Mar 31, 2026 |
| ORBIMED ADVISORS LLC | 475,165 | 7.1M $ | as of Mar 31, 2026 |
| JENNISON ASSOCIATES LLC | 470,775 | 7M $ | as of Mar 31, 2026 |
| Caption Management, LLC | 455,000 | 6.8M $ | as of Mar 31, 2026 |
| Soleus Capital Management, L.P. | 441,978 | 6.6M $ | as of Mar 31, 2026 |
| BNP PARIBAS FINANCIAL MARKETS | 422,781 | 6.3M $ | as of Mar 31, 2026 |
| KENNEDY CAPITAL MANAGEMENT LLC | 387,982 | 5.8M $ | as of Mar 31, 2026 |
| DV Trading LLC | 360,064 | 5.4M $ | as of Mar 31, 2026 |
Declared shareholders of AVALO THERAPEUTICS INC
There are 12 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| FMR LLC and 1 other | 10.80 % | 5,737,966 | as of Jul 31, 2026 · SCHEDULE 13G |
| Deep Track Capital, LP and 2 others | 6.87 % | 3,610,000 | as of Jun 30, 2026 · SCHEDULE 13G |
| BlackRock, Inc. | 6.50 % | 3,415,731 | as of Jun 30, 2026 · SCHEDULE 13G |
| RA Capital Management, L.P. and 3 others | 6.30 % | 3,483,099 | as of Jun 30, 2026 · SCHEDULE 13G |
| Caligan Partners LP and 1 other | 5.90 % | 3,163,866 | as of Jun 30, 2026 · SCHEDULE 13G |
| Affinity Asset Advisors, LLC and 1 other | 5.50 % | 2,900,000 | as of Jun 30, 2026 · SCHEDULE 13G |
| STATE STREET CORPORATION | 5.50 % | 2,889,287 | as of Jun 30, 2026 · SCHEDULE 13G |
| BIOTECHNOLOGY VALUE FUND L P and 9 others | 5.30 % | 2,801,545 | as of Jun 30, 2026 · SCHEDULE 13G |
| Avoro Capital Advisors LLC and 1 other | 4.44 % | 2,333,333 | as of Jun 30, 2026 · SCHEDULE 13G |
| Nantahala Capital Management, LLC and 2 others | 3.54 % | 1,862,250 | as of Jun 30, 2026 · SCHEDULE 13G |
| Millennium Management LLC and 2 others | 0.00 % | 9,857 | as of Jun 30, 2026 · SCHEDULE 13G |
| T. Rowe Price Investment Management, Inc. | 0.00 % | 3,670 | as of Jun 30, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Fund shareholders of AVALO THERAPEUTICS INC". https://titelia.com/en/stocks/avalo-therapeutics-inc-US05338F3064